title: Association studies of the adenosine A2a receptor (1976T > C) genetic polymorphism in Parkinson's disease and schizophrenia.
abstract: Given the implications with respect to the pathogenesis of dopaminergic dysfunction in schizophrenia and Parkinson's disease (PD), as well as the reciprocal antagonistic interactions between adenosine A2a receptor (A2aAR) and the dopamine D2 receptors, A2aAR may be a candidate gene conferring susceptibility to PD or schizophrenia. In this study, we tested the hypothesis that the A2aAR 1976T > C genetic variant confers susceptibility to or is related to the onset age of schizophrenia or PD using a sample population consisting of 94 PD and 227 schizophrenic patients. We also tested whether the A2aAR 1976T > C relates to antipsychotic-induced tardive dyskinesia in the schizophrenic population. The results demonstrated that in comparing PD patients and controls the distribution of the A2aAR 1976T > C genotypes (P=0.788) and alleles (P=0.702) did not vary significantly. Furthermore, the PD onset age was not significantly different amongst the three A2aAR 1976T > C genotypic groups. In comparing schizophrenic patients and controls, the distribution of the A2aAR genotypes (P=0.330) and alleles (P=0.632) also did not differ significantly. The onset age of schizophrenia and tardive dyskinesia (evaluated with Abnormal Involuntary Movements Scale) were similar within the three A2aAR genotypic groups. Our findings suggest that it is unlikely that the A2aAR 1976T > C polymorphism plays a major role in the pathogenesis of PD, schizophrenia, or antipsychotic-induced tardive dyskinesia in the Chinese population.
authors.affiliation: Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
authors.forename: C-J
authors.initials: CJ
authors.lastname: Hong
authors.forename: H-C
authors.initials: HC
authors.lastname: Liu
authors.forename: T-Y
authors.initials: TY
authors.lastname: Liu
authors.forename: D-L
authors.initials: DL
authors.lastname: Liao
authors.forename: S-J
authors.initials: SJ
authors.lastname: Tsai
mesh_terms: D017677:Age Distribution; D017668:Age of Onset; D000368:Aged; D044466:Asian People; D001483:Base Sequence / Q000235:genetics; D001921:Brain / Q000378:metabolism* / Q000503:physiopathology; D001923:Brain Chemistry / Q000235:genetics; D003596:Cytosine / Q000378:metabolism; D004252:DNA Mutational Analysis; D004409:Dyskinesia, Drug-Induced / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D017354:Point Mutation / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D043705:Receptor, Adenosine A2A / Q000235:genetics*; D012559:Schizophrenia / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D017678:Sex Distribution; D013624:Taiwan; D013941:Thymine / Q000378:metabolism
chemical_list: D043705:Receptor, Adenosine A2A; D003596:Cytosine; D013941:Thymine
references.citation: Eur J Neurosci. 2001 Oct;14(8):1287-93
references.pmid: 11703457
references.citation: J Neurochem. 1995 Nov;65(5):2057-64
references.pmid: 7595490
references.citation: J Clin Pharm Ther. 2000 Apr;25(2):131-7
references.pmid: 10849191
references.citation: Am J Med Genet. 2000 Spring;97(1):45-51
references.pmid: 10813803
references.citation: Neurosci Lett. 1991 Sep 16;130(2):162-4
references.pmid: 1665549
references.citation: Eur Neurol. 2002;48(4):207-9
references.pmid: 12422069
references.citation: Neuropsychopharmacology. 2003 Sep;28(9):1694-702
references.pmid: 12825092
references.citation: Mol Psychiatry. 1998 Jan;3(1):81-5
references.pmid: 9491818
references.citation: J Neural Transm (Vienna). 1996;103(12):1447-55
references.pmid: 9029412
references.citation: Trends Pharmacol Sci. 2000 Sep;21(9):341-6
references.pmid: 10973087
references.citation: Neurology. 2003 Dec 9;61(11 Suppl 6):S5-9
references.pmid: 14663001
references.citation: Neuroreport. 2003 Mar 3;14(3):313-6
references.pmid: 12634474
references.citation: Biol Psychiatry. 1990 Jul 1;28(1):35-40
references.pmid: 2375945
references.citation: Neuroscience. 1994 Dec;63(3):765-73
references.pmid: 7898676
references.citation: Exp Neurol. 2003 Nov;184(1):285-94
references.pmid: 14637099
references.citation: Neuropsychopharmacology. 2004 Mar;29(3):558-65
references.pmid: 14666117
references.citation: Med Hypotheses. 2005;64(1):197-200
references.pmid: 15533641
references.citation: Neuropsychopharmacology. 1999 Jan;20(1):44-51
references.pmid: 9885784
references.citation: Arch Neurol. 1996 Jan;53(1):66-71
references.pmid: 8599561
references.citation: J Neural Transm (Vienna). 2002 Apr;109(4):483-8
references.pmid: 11956967
references.citation: J Neurosci. 2002 Feb 1;22(3):1054-62
references.pmid: 11826134
references.citation: Neurology. 2003 Aug 12;61(3):293-6
references.pmid: 12913186
references.citation: Parkinsonism Relat Disord. 2004 Jul;10(5):265-71
references.pmid: 15196504
references.citation: Gen Pharmacol. 1998 Oct;31(4):553-61
references.pmid: 9792214
references.citation: Psychopharmacology (Berl). 1994 Nov;116(3):279-84
references.pmid: 7892417
references.citation: Mol Psychiatry. 1997 Jul;2(4):270-3
references.pmid: 9246659
references.citation: Schizophr Res. 1998 Jul 27;32(2):107-13
references.pmid: 9713906
references.citation: Clin Neuropharmacol. 2002 Jan-Feb;25(1):25-31
references.pmid: 11852293